Andrew Cheng - Gilead Sciences President

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>GIL</div>
GILD -- USA Stock  


Dr. Andrew Cheng was appointed Executive Vice President Clinical Research and Development Operations and Chief Medical Officer of the Company effective on April 2018
  President Since 2018      
650 574-3000  www.gilead.com
Cheng joined Gilead in 1999 to lead company developmentstage programs in HIV/AIDS. He received additional responsibility for the company Development Operations organization in 2009 and was named Executive Vice President in 2015. Under Dr. Cheng leadership, Gilead has developed and received regulatory approval for medicines that have transformed care for millions of people around the world with HIV, viral hepatitis and other serious illnesses. Prior to joining Gilead, Dr. Cheng trained in internal medicine at the University of California, Los Angeles. He received his medical degree and PhD in Cellular and Molecular Biology from Columbia University and his undergraduate degree from the Johns Hopkins University.

Management Efficiency

The company currently holds 28.84 B in liabilities with Debt to Equity (D/E) ratio of 139.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences has Current Ratio of 3.0 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Michael HolstonMerck Company
Melissa BarnesEli Lilly And Company
Ashley WatsonMerck Company
Robert StewartAllergan Plc
Philippe SchaisonAllergan Plc
Luke MielsAstrazeneca PLC
Jennifer ZacharyMerck Company
Phil ThomsonGlaxoSmithKline PLC
Albert BourlaPfizer
Matthew WalshAllergan Plc
Wayne SwantonAllergan Plc
Rady JohnsonPfizer
Paul BiondiBristol Myers Squibb Company
Adam DubowBristol Myers Squibb Company
Michael NallyMerck Company
CDavid NicholsonAllergan Plc
Christopher BoernerBristol Myers Squibb Company
Angela HwangPfizer
Kathy WengelJohnson Johnson
Fiona CicconiAstrazeneca PLC
Ann PowellBristol Myers Squibb Company

Company Summary

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange.Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 11,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Gilead Sciences Leadership Team

Kathleen Watson, Executive Vice President - Human ResourcesView
John McHutchison, Executive Vice President - Clinical ResearchView
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development OperationsView
John Martin, Chairman and CEOView
Andrew Dickinson, Executive Vice President - Corporate Development and StrategyView
Gayle Wilson, Independent DirectorView
Daniel ODay, Chairman of the Board, CEOView
Jacqueline Barton, DirectorView
Brett Pletcher, Executive VP and General CounselView
William Lee, Executive Vice President - ResearchView
John Madigan, Independent DirectorView
Martin Silverstein, Executive Vice President - StrategyView
Kevin Lofton, Independent DirectorView
Paul Carter, Executive Vice President - Commercial OperationsView
Gregg Alton, Executive VP of Corporate and Medical Affairs and SecretaryView
Diana Brainard, Senior Vice President HIV and Emerging Viral InfectionsView
Carla Hills, Independent DirectorView
John Cogan, Lead Independent DirectorView
John Milligan, Pres and COOView
Nicholas Moore, Independent DirectorView
James Meyers, Executive Vice President - Worldwide Commercial OperationsView
Katie Watson, Executive Vice President of Human ResourcesView
Kelly Kramer, DirectorView
Johanna Mercier, Chief Commercial OfficerView
Jyoti Mehra, Executive Vice President of Human ResourcesView
Laura Hamill, Executive Vice President - Worldwide Commercial OperationsView
Robin Washington, CFO and Executive VPView
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandDView
Per WoldOlsen, Independent DirectorView
Harish Manwani, DirectorView
Taiyin Yang, Executive Vice President - Pharmaceutical Development and ManufacturingView
Kevin Young, COOView
Etienne Davignon, Independent DirectorView
Richard Whitley, Independent DirectorView

Stock Performance Indicators

Current Sentiment - GILD

Gilead Sciences Investor Sentiment

Majority of Macroaxis users are currently bullish on Gilead Sciences. What is your judgment towards investing in Gilead Sciences? Are you bullish or bearish?
98% Bullish
2% Bearish

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.